Have a feature idea you'd love to see implemented?
Let us know!
SYRE Spyre Therapeutics Inc.
Price (delayed)
$27
Market cap
$1.39B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.48
Enterprise value
$1.32B
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of
Highlights
SYRE's EPS has soared by 97% YoY but it is down by 16% QoQ
Spyre Therapeutics's quick ratio has shrunk by 63% QoQ but it has surged by 58% YoY
The gross profit has dropped by 100% year-on-year
SYRE's revenue has shrunk by 100% YoY
Key stats
What are the main financial stats of SYRE
Market
Valuations
Earnings
Shares outstanding
51.43M
Market cap
$1.39B
Enterprise value
$1.32B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$214.85M
EBITDA
-$214.85M
Free cash flow
-$151.25M
Per share
Balance sheet
Liquidity
EPS
-$1.48
Free cash flow per share
-$2.97
Book value per share
$6.45
Revenue per share
$0
TBVPS
$8.27
Total assets
$421.09M
Total liabilities
$93.7M
Debt
$0
Equity
$327.39M
Working capital
$363.54M
Debt to equity
0
Current ratio
7.32
Quick ratio
7.2
Net debt/EBITDA
0.33
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-51%
Return on equity
-82.8%
Return on invested capital
-86.1%
Return on capital employed
-59.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SYRE stock price
How has the Spyre Therapeutics stock price performed over time
Intraday
-1.82%
1 week
-13.66%
1 month
-16.74%
1 year
170.81%
YTD
25.46%
QTD
-8.19%
Financial performance
How have Spyre Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$193.23M
Net income
-$214.9M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
SYRE's revenue has shrunk by 100% YoY
The net income has increased by 27% year-on-year but it has declined by 16% since the previous quarter
Spyre Therapeutics's operating income has decreased by 24% QoQ but it has increased by 10% YoY
Growth
What is Spyre Therapeutics's growth rate over time
Valuation
What is Spyre Therapeutics stock price valuation
P/E
N/A
P/B
4.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SYRE's EPS has soared by 97% YoY but it is down by 16% QoQ
SYRE's P/B is 61% above its 5-year quarterly average of 2.6 and 2.2% above its last 4 quarters average of 4.1
The company's equity fell by 13% QoQ
SYRE's revenue has shrunk by 100% YoY
Efficiency
How efficient is Spyre Therapeutics business performance
Spyre Therapeutics's ROA has soared by 75% YoY
The company's return on equity rose by 48% QoQ
SYRE's return on invested capital is up by 10% since the previous quarter
Dividends
What is SYRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SYRE.
Financial health
How did Spyre Therapeutics financials performed over time
Spyre Therapeutics's total assets has surged by 103% YoY but it has decreased by 3.4% QoQ
SYRE's current ratio has shrunk by 63% QoQ but it has soared by 59% YoY
Spyre Therapeutics's debt is 100% lower than its equity
The company's equity fell by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.